Newer one-piece IOL offers excellent visual acuity, says surgeon
November 1st 2008The state-of-the-art material and design of a novel one-piece IOL can offer refractive stability and predictability, according to Daniel A. Black, MBBS, FRACO, FRACS. This newer IOL rivals other more established IOLs and may soon become the gold-standard treatment in cataract procedures, he said.
2-year data promising for dual-optic lens; centers well and is easy to implant, surgeon says
November 1st 2008Two lenses may be better than one. In a prospective trial of 30 eyes, a dual-accommodating IOL, with a high-diopter anterior optic and a minus-power posterior optic, provided good distance visual acuity, depth of focus, and a good safety profile.
ESCRS Endophthalmitis Study: Intracameral cefuroxime injections prevent endophthalmitis
November 1st 2008Prophylactic intracameral cefuroxime injections prevent the development of endophthalmitis after cataract surgery, according to results of the European Society of Cataract and Refractive Surgeons Endophthalmitis Study. The finding remains controversial in the United States, where cefuroxime has not been approved by the FDA and the standard of care to prevent endophthalmitis after cataract surgery is the administration of preoperative, perioperative, and postoperative topical fluoroquinolone drops.
Severity determines intraoperative floppy iris syndrome management approach
November 1st 2008A cataract surgeon who first identified intraoperative floppy iris syndrome (IFIS) and its association with tamsulosin describes several approaches to managing the surgical complication. The approach a surgeon uses will depend on the severity of IFIS, he says.
You can negotiate with health plans
November 1st 2008Depending on your location, your specialty, and the size of your practice, insurers may actually want to keep you happy, especially if you threaten to walk away from a bad deal. If nothing else, negotiations may reveal that lowball reimbursement for a particular code is nothing more than an inadvertent mistake that most insurers are willing to correct.
How to collect past-due payments from patients without scaring them away
November 1st 2008Physician groups are adopting tougher collection tactics, largely in response to tough times. What compounds their problem of skimpy third-party reimbursements and rising overhead is having to depend on patients for a bigger portion of their revenue stream-a result of the rising number of uninsured and the growth of high-deductible health plans.
Evaluating your competition: industry and non-industry
November 1st 2008Losing even one patient to another local practice is one too many. To achieve and maintain an edge in the LASIK market, you've got to stay on top of your competitors with research and analysis, and regularly evaluate where you fit in terms of image and consumer perception.
New spectral-domain optical coherence tomography algorithms can provide objective retina exam
November 1st 2008Use of spectral-domain optical coherence tomography with automated image processing seems to provide more objective and potentially more reproducible assessments of the optic nerve head when compared with ophthalmologists' assessments of conventional fundus photos.
ISTA Pharmaceuticals reaches funding agreement
November 1st 2008ISTA Pharmaceuticals, Inc. has entered into an agreement with Deerfield Management, Sprout, and Sanderling Ventures, three of its long-term shareholders, to provide it with up to $65 million in financing through a flexible credit facility.
Intracameral triamcinolone may be viable PKP treatment
November 1st 2008Topical, periocular, and/or systemic corticosteroids typically are used to treat corneal endothelial graft rejection. When those modalities fail, experience in a series of five eyes suggests intracameral triamcinolone acetonide may be worth considering.
Take a new look at existing devices, surgeon suggests
November 1st 2008The high-tech devices available today are changing the way ophthalmology is practiced. According to the surgeon, the new technology found in state-of-the-art optical coherence tomography goes much further than assisting ophthalmologists in the diagnostics of anterior eye and retinal disorders.
Fixed-combination therapies offer option for greater pressure reduction
November 1st 2008Monotherapy is usually the first step in glaucoma therapy, but when IOP is not sufficiently lowered with a single agent, a fixed combination can be considered. The advantages, limitations, and features of fixed combinations of IOP-lowering agents available worldwide are reviewed.
Acucela, Otsuka enter into agreements
November 1st 2008Acucela Inc. and Otsuka Pharmaceutical Co. Ltd. have entered into agreements to co-develop Otsuka's proprietary compound for the treatment of dry eye (Rebamipide), which is in phase III clinical trials in the United States, as well as Acucela's lead compound (ACU-4429), which is in phase I clinical trials for non-exudative (dry) age-related macular degeneration in the United States.